Application of Nano-Delivery Technology in Tumor Immunotherapy

Shaopu Huang

doi:10.54097/f91dx816

Authors

Shaopu Huang

DOI:

https://doi.org/10.54097/f91dx816

Keywords:

Cancer immunotherapy; Nano-carrier; Gene nanomedicine; PD-1/PD-L1; T cell infiltration.

Abstract

Immunotherapy has made great progress in cancer treatment, showing amazing results in clinical applications. However, a number of factors contribute to a lower response to immunotherapy in some cancer patients. T cells play an important role in tumor immune response. However, it is difficult to achieve the directed infiltration of T cells by current methods. In addition, the expression of non-specific drugs in normal tissues may cause serious adverse reactions. Now a new strategy is needed to increase the infiltration of T cells, increase the specificity of drug expression, improve the therapeutic effect and reduce the risk of adverse reactions. Nanocarriers can be enriched in tumor tissues through a series of effects, and tumor-specific genes can ensure that drugs will not work in normal tissues, so nanoparticles can be used to encapsulate tumor-specific gene nanocarriers to achieve precise treatment. In this paper, the types of nanocarriers and gene drugs and the application of this technology in practical research are introduced in detail. Finally, the prospect and challenge of future development are expressed.

Downloads

Download data is not yet available.

References

[1] Dobosz P, Dzieciatkowski T. The Intriguing History of Cancer Immunotherapy. Front Immunol, 2019, 10: 2965.

[2] Manso T, Kushwaha A, Abdoliahi N, et al. Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB. Front Immunol, 2023, 14: 1129323.

[3] Shuptrine C W, Surana R, Weiner L M. Monoclonal antibodies for the treatment of cancer. Semin Cancer Biol, 2012, 22(1): 3-13.

[4] Goodman A, Patel S P, Kurzrock R. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol, 2017, 14(4): 203-20.

[5] Bashor C J, Hilton I B, Bandukwala H, et al. Engineering the next generation of cell-based therapeutics. Nat Rev Drug Discov, 2022, 21(9): 655-75.

[6] Pan K, Farrukh H, Chittepu V, et al. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res, 2022, 41(1): 119.

[7] June C H, O'connor R S, Kawalekar O U, et al. CAR T cell immunotherapy for human cancer. Science, 2018, 359(6382): 1361-5.

[8] Choudhery M S, Arif T, Mahmood R, et al. CAR-T-Cell-Based Cancer Immunotherapies: Potentials, Limitations, and Future Prospects. J Clin Med, 2024, 13(11).

[9] Dunbar C E, High K A, Joung J K, et al. Gene therapy comes of age. Science, 2018, 359(6372).

[10] Mendes B B, Conniot J, Avital A, et al. Nanodelivery of nucleic acids. Nat Rev Methods Primers, 2022,2.

[11] Montano-Samaniego M, Bravo-Estupinan D M, Mendez-Guerrero O, et al. Strategies for Targeting Gene Therapy in Cancer Cells with Tumor-Specific Promoters. Front Oncol, 2020, 10: 605380.

[12] Xu C F, Iqbal S, Shen S, et al. Development of "CLAN" Nanomedicine for Nucleic Acid Therapeutics. Small, 2019, 15(16): e1900055.